1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Cytochrome P450

Cytochrome P450

CYPs

Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10505
    Orteronel
    Inhibitor 99.90%
    Orteronel (TAK-700) is a highly selective inhibitor of human 17,20-lyase (CYP17) with IC50 of 38 nM, and exhibits >1000-fold selectivity over other CYPs such as 11-hydroxylase and CYP3A4.
    Orteronel
  • HY-132845
    Utreloxastat
    Inhibitor 99.69%
    Utreloxastat (PTC857) is an orally active and blood-brain barrier-permeable 15-lipooxygenase inhibitor. Utreloxastat is a weak inhibitor of CYP1A2 and 2B6 with an IC50 of >5.3 μM. Utreloxastat reduces oxidative stress and inhibits the consumption of reduced glutathione and ferroptosis. Utreloxastat can be used in the study of neurodegenerative diseases characterized by high levels of oxidative stress and mitochondrial pathology, such as amyotrophic lateral sclerosisc.
    Utreloxastat
  • HY-15996
    Seviteronel
    Inhibitor 99.83%
    Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM) and an AR antagonist. Seviteronel demonstrates both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition.
    Seviteronel
  • HY-111430
    1-Ethynylnaphthalene
    Inhibitor 99.27%
    1-Ethynylnaphthalene is a selective inhibitor of cytochrome P450 1B1. 1-Ethynylnaphthalene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    1-Ethynylnaphthalene
  • HY-B0615A
    Moricizine Hydrochloride
    Inhibitor 98.0%
    Moricizine Hydrochloride (EN 313) is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period.
    Moricizine Hydrochloride
  • HY-163436
    F44-A13
    Inducer
    F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders.
    F44-A13
  • HY-G0007
    Omeprazole sulfone
    99.23%
    Omeprazole sulfone is one of the major metabolites of Omeprazole (HY-B0113). Omeprazole sulfone is generated via sulfoxidation mediated by cytochrome P450 3A4 (CYP3A4).
    Omeprazole sulfone
  • HY-B0237
    Aminoglutethimide
    Inhibitor 98.79%
    Aminoglutethimide is an aromatase inhibitor with IC50 of 10 μM.
    Aminoglutethimide
  • HY-135331
    N-Desmethyl-Apalutamide
    Modulator 99.68%
    N-Desmethyl Apalutamide is an active metabolite of Apalutamide. N-Desmethyl Apalutamide is a less potent antagonist of the androgen receptor and is responsible for one-third of the activity of Apalutamide. The formation of N-Desmethyl Apalutamide mediated predominantly by CYP2C8 and CYP3A4. N-Desmethyl Apalutamide is moderate to strong CYP3A4 and CYP2B6 inducer and has an excellent plasma-proteins bound concentration.
    N-Desmethyl-Apalutamide
  • HY-W019847
    Azamulin
    Inhibitor
    Azamulin is an irreversible, highly selective inhibitior of human CYP3Aa. Azamulin has CYP3A inhibition activity with IC50 values range from 0.03-0.24 μM. Azamulin can be used for the research of metabolism and antiinfection.
    Azamulin
  • HY-B1462R
    Chlorzoxazone (Standard)
    Modulator
    Chlorzoxazone (Standard) is the analytical standard of Chlorzoxazone. This product is intended for research and analytical applications.
    Chlorzoxazone (Standard)
  • HY-121188
    DDMS
    Inhibitor 99.19%
    DDMS (Dibromo-dodecenyl-methylsulfimide) is a selective 20-HETE production inhibitor. DDMS attenuates the vasodilatory response to sodium nitroprusside (SNP).
    DDMS
  • HY-B1880
    Oxadiazon
    Inhibitor 98.51%
    Oxadiazon is an orally active herbicide. Oxadiazon reduces hepatic cytochrome P450 levels. Oxadiazon increases palmitoyl CoA oxidase, acetyl carnitine transferase, and hepatic ALAS activity. Oxadiazon induces hepatomegaly and experimental porphyria. Oxadiazon controls weeds. Oxadiazon may be used in neurodegenerative disease research.
    Oxadiazon
  • HY-B0876A
    Fomepizole hydrochloride
    Inhibitor 99.85%
    Fomepizole (4-Methylpyrazole) hydrochloride is a potent and orally active cytochrome P450 (CYP2E1) inhibitor. Fomepizole hydrochloride is a competitive inhibitor of the enzyme alcohol dehydrogenase. Fomepizole hydrochloride blocks further conversion of methanol and ethylene glycol to toxic metabolites. Fomepizole hydrochloride has the potential for an antidote for ethylene glycol or methanol poisoning.
    Fomepizole hydrochloride
  • HY-N12257
    Antimycin A2
    Inhibitor 99.0%
    Antimycin A2 is the component of the antibiotic antimycin A. Antimycin A is an antibiotic, that exhibits inhibitory activity against fungi and some insects through inhibition of respiration and cytochrome b reoxidation.
    Antimycin A2
  • HY-B1042
    Oxolamine citrate
    Inhibitor 99.87%
    Oxolamine citrate (SKF-9976 citrate) is an orally active antitussive. Oxolamine citrate can inhibit CYP2B1/2. Oxolamine citrate has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine citrate increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine citrate can be used in respiratory disease research.
    Oxolamine citrate
  • HY-70013S
    Abiraterone-d4
    Inhibitor 98.0%
    Abiraterone-d4 is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
    Abiraterone-d<sub>4</sub>
  • HY-109040
    Quilseconazole
    Inhibitor 98.61%
    Quilseconazole (VT-1129) is an orally active, highly selective fungal cytochrome P450 enzyme Cyp51 inhibitor that can cross the blood-brain barrier. Quilseconazole prevents the synthesis of ergosterol, an important component of the fungal cell membrane, by inhibiting Cyp51. Quilseconazole has minimal effects on human CYP enzymes. Quilseconazole has antifungal activity and can be used in the study of cryptococcal meningitis and other diseases.
    Quilseconazole
  • HY-N0688
    Linderane
    Inhibitor 99.61%
    Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp.
    Linderane
  • HY-151810
    TP0472993
    Inhibitor 98.22%
    CYP4A11/CYP4F2-IN-2 is a potent and orally active dual inhibitor of cytochrome P450 (CYP) 4A11 and CYP4F2, with IC50s of 140 nM and 40 nM, respectively. CYP4A11/CYP4F2-IN-2 has potential for the research of renal diseases.
    TP0472993
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.